NeoGenomics (NEO) – Accesswire
-
NeoGenomics to Appeal Ruling
-
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
-
NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference
-
NeoGenomics Reports Third Quarter 2023 Results
-
NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios
-
NeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023
-
NeoGenomics Reports Second Quarter 2023 Results
-
NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
-
NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023
-
NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors
-
NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
-
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
-
NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
-
NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO
-
NeoGenomics Reports First Quarter 2023 Results
-
NeoGenomics to Participate at the BofA Securities 2023 Healthcare Conference
-
NeoGenomics to Announce First Quarter 2023 Financial Results
-
NeoGenomics to Participate at the 22nd Annual Needham Virtual Healthcare Conference
-
NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023
-
NeoGenomics to Host Investor Day on April 4, 2023
-
NeoGenomics Announces Commercial Availability of the RaDaR(R) Molecular Residual Disease Test
-
NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM) - Solid Tumor CGP and Neo Comprehensive(TM) - Myeloid Disorders CGP
-
NeoGenomics to Present at the 44th Annual Raymond James Institutional Investors Conference
-
NeoGenomics Reports Fourth Quarter and Full Year 2022 Results
-
RaDaR(R) Assay Demonstrates Clinical Potential for Helping Oncologists Determine Whether or Not Muscle-Invasive Bladder Cancer Patients Undergo Radical Surgery
-
NeoGenomics Schedules its Fourth Quarter and Full Year 2022 Earnings Release for February 23, 2023
-
NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
NeoGenomics Announces Chief Financial Officer Transition
-
RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease
-
NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)
-
NeoGenomics Reports Third Quarter 2022 Results
-
NeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of Directors
-
NeoGenomics Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch
-
NeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022
-
NeoGenomics and Liquid Biopsy Subsidiary Inivata and Collaborators to Present New Data at ESMO Congress 2022
-
NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
NeoGenomics Reports Revenue of $125 Million in the Second Quarter
-
NeoGenomics Announces Chief Executive Officer Appointment
-
NeoGenomics Schedules its Second Quarter 2022 Earnings Release for August 9, 2022
-
NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer
-
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
-
NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory
-
NeoGenomics Appoints Lynn Tetrault Interim CEO
-
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR(R) MRD and InVisionFirst(R)-Lung Tests at the 2022 ASCO Annual Meeting
-
NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary
-
NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference
-
NeoGenomics Reports Revenue of $117 Million in the First Quarter
-
NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay
-
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay MRD Assay at AACR 2022
-
NeoGenomics, Inc. Expands Its Global Strategic Partnership Initiatives with Biognosys AG on Multiple Next Generation Proteomics Solutions Supporting Biopharma R&D
Back to NEO Stock Lookup
